14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.019 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation The generation of immortalized human B-lymphocytes secreting neutralizing monoclonal antibodies against Dengue virus E. Teoh National University of Singapore, Singapore, Singapore Background: Dengue is an important re-emerging disease affecting humans in more than 100 countries worldwide. Presently, over 2.5 billion people live in risk areas and 50 to 100 million people suffer from dengue fever (DF) each year. The World health Organization (WHO) estimates that currently 500,000 cases of Dengue Hemorrahagic Fever / Dengue Shock Syndrome (DHF/DSS) and more than 20,000 deaths occur per year. At the moment, there are no effective vaccines or drugs available to prevent or treat Dengue disease. Chimeric viruses, DNA, inactivated and subunit recombinant vaccines are also of interest but they are still in preclinical development. At present, vaccine may not be available for the next 3-5 years because the complex immune reactions that are involved in dengue immuno-pathogenesis needs further clarification. In this study, we propose a novel method of immortalizing and cloning Dengue virus specific B lymphocytes from convalescent patients secreting neutralizing antibodies. Upon which, DNA from these B lymphocytes were extracted and sequenced. Sequential cloning method was employed to clone in the variable light (VL) chain and variable heavy (VH) chain fragments into the IgG1 framework vector. This recombinant vector was transfected into suspension human embryonic kidney (HEK) 293 cells for transient expression of the dengue-neutralizing antibodies belonging to the various IgG subclasses. The antibodies isolated will prove useful tools for studying the immunology of Dengue virus infections and as possible future therapeutic reagents to prevent virus dissemination in infected individuals. Methods: Ebv immortalization. ELISA. PRNT. Immunofluorescent Microscopy. Molecular Cloning. Antibody purification. Results: Antibody generated. Conclusion: Human antibody responses are important to resolve Dengue infections naturally and the best strategy is to isolate and produce the anti-dengue antibodies that resolve infections in human patients. These therapeutic antibodies are have predictable pharmacokinetics properties and display low toxicological risk. A research collaboration involving the National University of Singapore (NUS), Novartis Institute of Tropical Diseases, Singapore (NITD) and Defence Science National Laboratories, Singapore (DSO) aims to produce human monoclonal antibodies (mAb), that can efficiently neutralize the Dengue virus. Each antibody will be fully cloned and expressed recombinantly as IgG class.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.020 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Factors Contributing to Uptake of the Publicly-funded HPV vaccine in Toronto H. Meghani 1 , V. Dubey 2 , O. Kadri 2 , A. Mathur 2 , J. Cameron 2 , K. Beckermann 2 1 University of Toronto, Toronto, ON, Canada, 2 Toronto Public Health, Toronto, ON, Canada Background: In August 2007 the Government of Ontario announced that, for the first time, it was offering the quadravalent HPV vaccine to grade 8 females in all Toronto schools beginning September 2007. Uptake of the vaccine in the 2007/2008 province-wide program was much lower than anticipated. The provincial HPV vaccination rate was 58% for the first dose, which was lower than other school-based vaccination programs. For a vaccine with such far-reaching impact on a woman’s health, this is a disappointing and not well understood outcome. We assessed parental factors for and against the HPV vaccine. Methods: A random sample of parents of grade 8 females in Toronto who were eligible for the publicly-funded HPV vaccine in the 2007-2008 academic session were asked to respond to questions regarding the HPV vaccine program in Toronto. We conducted telephone interviews and used standardized questionnaires to capture data. We conducted bivariate statistics to compare the responses of parents who allowed their daughters to be vaccinated against HPV with those of parents who did not. Multivariate logistic regression statistics was calculated with SPSS to identify the predictive factors that were significantly associated with HPV vaccine uptake. Results: Of the 138 respondents, 75.4% had vaccinated their daughters. Concern over safety of the vaccine (27.3%) and inadequate information (21.2%) were the most commonly reported reasons given by parents to not allow their daughters to be vaccinated. Religious affiliation was not associated with a difference in parental decision to vaccinate. Parents whose daughters were vaccinated were more likely to agree with the importance of vaccination prior to sexual activity onset (OR=10.46, 95% CI: 1.72-63.59, p
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208: When citing these abstracts please
Page 257: When citing these abstracts please
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

Create successful ePaper yourself

Delete template?

Save as template?